UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May 2025

Commission File Number: 001-40488

MOLECULAR PARTNERS AG

(Exact name of registrant as specified in its charter)

Wagistrasse 14

8952 Zürich-Schlieren

Switzerland

Telephone: +41 447557700

(Address of registrant’s principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

EXPLANATORY NOTE

Molecular Partners AG (the "Company") is filing this Form 6-K to furnish (i) a press release the Company issued on May 15, 2025 and (ii) condensed consolidated interim financial statements (unaudited) as of, and for, the three months ended, March 31, 2025 (including accompanying notes thereto), which are furnished herewith as Exhibits 99.1 and 99.2, respectively.

Exhibit 99.1 (excluding any quotes of management) and Exhibit 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registrant’s Registration Statements on Form F-3 (File No. 333-286488) and Form S-8 (File Nos. 333-272974 and 333-280491) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Additionally, attached as Exhibit 15.1 to this Report on Form 6-K is a consent of KPMG AG, the Company’s independent registered public accounting firm. The original consent filed on March 6, 2025 as Exhibit 15.1 the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024 did not include references to the Company’s Registration Statements on Form S-8 (File Nos. 333-272974 and 333-280491). The consent filed herewith does not change any previously reported financial results or other disclosure contained in the Company’s Annual Report on Form 20-F. Exhibit 15.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into such Registration Statements on Form S-8 (File Nos. 333-272974 and 333-280491) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.


Exhibit

15.1						Consent of KPMG AG, independent registered public accounting firm
99.1						Press Release May 15, 2025
99.2						Condensed consolidated interim financial statements (unaudited)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MOLECULAR PARTNERS AG

(Registrant)

Date: May 15, 2025 /s/ PATRICK AMSTUTZ

Name: Patrick Amstutz

Title: Chief Executive Officer

MOLECULAR PARTNERS AG 6-K